Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex